Back to top
more

Akoya Biosciences (AKYA)

(Delayed Data from NSDQ)

$2.11 USD

2.11
81,926

-0.01 (-0.47%)

Updated Nov 22, 2024 04:00 PM ET

After-Market: $2.11 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (64 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 5.26% and 25.39%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 22.28% and 74.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 549.35% and 487.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of -16.67% and 23.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 0.70% and 30.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 51.52% and 250.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akoya (AKYA) delivered earnings and revenue surprises of 18.52% and 1.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

by Zacks Equity Research

Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Strength Seen in Akoya (AKYA): Can Its 7.4% Jump Turn into More Strength?

by Zacks Equity Research

Akoya (AKYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag

by Zacks Equity Research

Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Abbott (ABT) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Cigna Group (CI) This Year?

by Zacks Equity Research

Here is how Cigna (CI) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.

Best Momentum Stocks to Buy for January 8th

by Zacks Equity Research

AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.

Sweta Killa headshot

5 Small-Cap Stocks to Play the January Effect

by Sweta Killa

Anavex Life Sciences (AVXL), Peakstone Realty Trust (PKST), AC Immune (ACIU), Getaround (GETR) and Akoya Biosciences (AKYA) could be solid picks to play the January Effect.

New Strong Buy Stocks for January 8th

by Zacks Equity Research

TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.

How Akoya Biosciences (AKYA) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Akoya Biosciences (AKYA) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

How Much Upside is Left in Akoya (AKYA)? Wall Street Analysts Think 86%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 86% in Akoya (AKYA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer, Inc. (SEER) delivered earnings and revenue surprises of 13.16% and 5.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.